2018
Chapter One Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies
Han X, Vesely MD. Chapter One Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. International Review Of Cytology 2018, 342: 1-25. PMID: 30635089, PMCID: PMC6487201, DOI: 10.1016/bs.ircmb.2018.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsT cellsT-lymphocyte antigen-4Monoclonal antibodiesInhibitory T cell receptorsCostimulatory receptor CD137Immunostimulatory monoclonal antibodiesUse of immunotherapeuticsT cell receptorAntitumor immunityDeath-1Antigen-4Immune surveillanceAgonist antibodyCostimulatory receptorsF. Macfarlane BurnetCancer cellsAntibodiesCancerReceptorsMacfarlane BurnetCellsGITRCD137CD27OX40
2013
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals Of The New York Academy Of Sciences 2013, 1284: 1-5. PMID: 23651186, PMCID: PMC3648872, DOI: 10.1111/nyas.12105.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune systemTumor-specific antigensHuman cancer patientsTumor-promoting actionsNascent tumor cellsAntitumor immunityTumor immunityCancer immunosurveillanceChronic inflammationPersonalized cancer therapyImmunogenic variantsCancer immunotherapyCancer patientsCancer immunoeditingT cellsAnimal modelsTumor variantsTumor progressionTumor cellsCancer cellsImmunityCancer therapyCancerAntigenImmunoselection
2012
Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research 2012, 72: 3987-3996. PMID: 22869585, PMCID: PMC4384890, DOI: 10.1158/0008-5472.can-12-1337.Peer-Reviewed Original ResearchConceptsIL-12IL-23Antibody treatmentImmune systemCD40 antibody treatmentIL‐12/23p40 antibodiesAutoimmune inflammatory disorderMonoclonal antibody treatmentOccult neoplasiaOccult cancerIL-17IL-23p19IL-12/23p40Immune controlInflammatory disordersTumor immunogenicityIL-4Malignant potentialCancer immunoeditingTumor outgrowthElimination phaseTumor growthTumor dormancyMutant cancersCancer cells